Arteriosclerosis (AS) presents a significant global health challenge, demanding innovative therapeutic strategies. This review explores the potential of nanoparticles (NPs) and mesenchymal stem cells (MSCs) as promising modalities for treating AS. NPs enable targeted drug delivery, while MSCs possess immunomodulatory and regenerative capabilities. We discuss recent advances in NP-based drug delivery systems tailored for AS treatment and highlight MSCs’ roles in modulating inflammation and promoting vascular repair. Additionally, we examine the synergistic effects of combining NPs and MSCs for enhanced therapeutic outcomes. Furthermore, this paper provides insights into targeting endothelial cells, T-cells, macrophages, lipid levels, and plaques in AS using MSCs. It also reviews various types of metal-based and non-metallic NPs utilized in AS therapy. This comprehensive overview underscores the potential synergies between MSCs and NPs in cardiovascular disease therapy, emphasizing the need for further research to fully realize their therapeutic implications. Graphical Abstract
Multiple sclerosis (MS) is the consequence of early-onset inflammatory demyelination and progressive neurodegenerative lesions in the central nervous system (CNS). Despite the unclear pathogenesis of MS, two main processes occur, oligodendrocyte repair and lipid metabolism. Nuclear receptors have been observed to have a role as ligand sensors, regulators of transcriptional factors, and modulators of gene expression. One member of this family, the retinoid X receptor (RXR), which forms a heterodimeric complex with liver X receptor (LXR), have been implicated in the pathophysiology of MS. Moreover, it has been expressed that LXR receptors play pivotal role in the regulation of inflammation, oxidative stress responses, and cholesterol metabolism in phagocytes in active MS lesions. This review aimed to study role of RXR and LXR in MS pathogenesis.